european end-to-end CDMO company, pharma services

Biologics

Why Europe is Becoming a Global Hub for Biologics Manufacturing

Biologics, Manufacturing
upstream development

Upstream Development for High Yield Biologics Production 

Biologics, Drug development, Manufacturing
biologics characterization

Biologics Characterization for Ensuring Product Quality and Consistency

Analytics, Biologics
Monoclonal Antibody Prophylaxis for Infectious Diseases

Monoclonal Antibody Prophylaxis for Infectious Diseases – Passive Immunization and Prevention

Monoclonal antibody, Vaccines
Analytical Lifecycle for Monoclonal Antibodies

From Research to Release: Mapping Mabion’s Full Analytical Lifecycle for Monoclonal Antibodies 

Analytics, Mabion, Monoclonal antibody
time to market strategy

Time to Market Strategy – 5 CDMO Tactics to Speed Up Biologic Launches

Biologics, Drug development, Manufacturing
antibodies development best practices

Antibodies Development Best Practices for CDMO Collaboration

Drug development, Manufacturing, Monoclonal antibody
UV-VIS spectrometry for protein concentration analysis

UV-VIS Spectrometry for Protein Concentration Analysis: Principles and Applications 

Analytics, Biologics, Proteins
Innovative biologics that are expected to be approved in 2025

Innovative Biologics – Expected Drug Approvals in 2025

Antibody-drug conjugates, Biologics, Bispecific antibody, Clinical trials, EMA, FDA, Monoclonal antibody, Vaccines